OPKO Health Completes Acquisition of Brazilian Pharmaceutical Company
OPKO Health, Inc. (NYSE: OPK) announced that is has completed the
acquisition of Silcon Comércio, Importacao E Exportacao de Produtos
Farmaceuticos e Cosmeticos Ltda.
Domiciled in Sao Paulo, Brazil, Silcon expands OPKO's presence in Latin
America and complements business activities of units in Chile and
Mexico, as well as permits commercialization of the OPKO 4KScore™
prostate cancer test in Brazil as a reference laboratory test while OPKO
obtains local approval to market its point of care microfluidics
disposable test cassettes.
Phillip Frost, M.D., OPKO's Chairman and Chief Executive Officer,
commented, "We are excited to establish our initial footprint in the
most important growth market in South America and initiate commercial
efforts towards the introduction of our 4Kscore™ test in the Brazilian
About OPKO Health, Inc.
We are a multi-national biopharmaceutical and diagnostics company that
seeks to establish industry-leading positions in large and rapidly
growing medical markets by leveraging our discovery, development and
commercialization expertise and our novel and proprietary technologies.
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding the benefits and synergies
resulting from the acquisition of Silcon, including whether OPKO's
portfolio of products in Latin America will grow and Silcon will provide
the anticipated cross marketing opportunities, whether Silcon
will provide a commercial platform that supports the near-term launch of
OPKO's 4Kscore™ in Brazil, the timing for the launch of the OPKO
4Kscore™, whether Silcon will enable OPKO to satisfy regulatory
requirements for doing business in Brazil,, the ability to obtain local
approval of OPKO's point of care microfluidics disposable test
cassettes, whether OPKO will be successful in migrating its 4Kscore™
onto the microfluidics disposable test cassettes, the potential benefits
of the OPKO 4Kscore™, whether OPKO or Silcon will be able to
successfully commercialize the OPKO 4Kscore™, as well as other
non-historical statements about our expectations, beliefs or intentions
regarding our business, technologies and products, financial condition,
strategies or prospects. Many factors could cause our actual activities
or results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include those
described in our filings with the Securities and Exchange Commission, as
well as risks inherent in funding, developing and obtaining regulatory
approvals of new, commercially-viable and competitive products and
treatments. In addition, forward-looking statements may also be
adversely affected by general market factors, competitive product
development, product availability, federal and state regulations and
legislation, the regulatory process for new products and indications,
manufacturing issues that may arise, patent positions and litigation,
among other factors. The forward-looking statements contained in this
press release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the safe-harbor
provisions of the PSLRA.
OPKO Health, Inc.
Steven D. Rubin, 305-575-4100
F. Rodriguez, 305-575-4100
Source: OPKO Health, Inc.
News Provided by Acquire Media
Close window | Back to top